Avid-19, overweight can affect the efficiency of vaccines

Two recently published Italian studies show that this concern can prove true.

Both studies include a m vaccine A RN ( BioNTech/Pfiser), managed for health care workers in Italy, without any other particular health problems.

The interval between the two doses was 21 days.

The first study included 248 subjects whose immune responses were assessed a week after the second dose of the vaccine.

He showed that a higher body mass index (BMI) was accompanied by a weaker concentration of antibodies in response to the vaccine.

The second study included 86 people whose immune responses were estimated one to four weeks after the second dose of the vaccine.

This study showed no changes in the immune response to BMI, but it showed that people with central overweight (beli James > 88 cm for women and > 102 cm for men) showed a weaker concentration of antibodies in response to the vaccine.

Moreover, this study showed that smoking and hypertension were accompanied by lower concentrations of antibodies, a first reported discovery in literature.

These observations, though initial, are of particular importance. If tested by other larger studies, they will influence health policy decisions to effectively plan possible repeated vaccines.